The team discovered the MRSA-fighting potential of a class of compounds already used to treat malaria and cancer, called quinazolines. The synthetic compound they developed out of the quinazolines showed promise as an antibacterial agent, earning the team a U.S. patent.
Despite the progress, the microbiologist leading the project, Lindsey Shaw, PhD, estimates the team is still likely another five years away from conducting clinical trials with humans.
More articles on MRSA:
4 risk factors for MRSA infections in Mississippi
New silver solution proves effective in killing MRSA
FDA provides clearance for Roche MRSA/SA test
